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Anna Gazumyan1, Melissa Cipolla1, Tania Kapoor1, Francesca Guidetti1, Kai-Hui Yao1, Jana Elsterová2,3, Dana Teislerová8,
Aleš Chrdle8,9,10, Václav Hönig2,3, Thiago Oliveira1, Anthony P. West Jr.4, Yu E. Lee4, Charles M. Rice7, Margaret R. MacDonald7,
Pamela J. Bjorkman4, Daniel Růžek2,3, Davide F. Robbiani1,5, and Michel C. Nussenzweig1,11
Tick-borne encephalitis virus (TBEV) is an emerging human pathogen that causes potentially fatal disease with no
specific treatment. Mouse monoclonal antibodies are protective against TBEV, but little is known about the human
antibody response to infection. Here, we report on the human neutralizing antibody response to TBEV in a cohort of
infected and vaccinated individuals. Expanded clones of memory B cells expressed closely related anti-envelope
domain III (EDIII) antibodies in both groups of volunteers. However, the most potent neutralizing antibodies, with IC50s
below 1 ng/ml, were found only in individuals who recovered from natural infection. These antibodies also neutralized
other tick-borne flaviviruses, including Langat, louping ill, Omsk hemorrhagic fever, Kyasanur forest disease, and
Powassan viruses. Structural analysis revealed a conserved epitope near the lateral ridge of EDIII adjoining the EDI–EDIII
hinge region. Prophylactic or early therapeutic antibody administration was effective at low doses in mice that were
lethally infected with TBEV.
Introduction
Tick-borne flaviviruses are responsible for a series of emerging
infectious diseases including fatal encephalitis. Like other fla-
viviruses, the tick-borne encephalitis virus (TBEV) envelope
protein (E) is composed of three structural domains (envelope
domains I–III [EDI–EDIII]; Füzik et al., 2018; Pulkkinen et al.,
2018). Mouse monoclonal antibodies against EDIII, an Ig-like
domain that mediates host cell attachment, are potent neutral-
izers of TBEV (Baykov et al., 2014; Füzik et al., 2018; Levanov
et al., 2010; Matveev et al., 2020; Phillpotts et al., 1985; Rey et al.,
1995; Yang et al., 2019).
TBEV is one of the six flaviviruses transmitted by ticks
causing human disease (Gould and Solomon, 2008; Kuno et al.,
1998; LaSala and Holbrook, 2010). These include Omsk hemor-
rhagic fever virus (OHFV) in Russia; Kyasanur forest disease
virus (KFDV) in India; Alkhurma virus in Saudi Arabia; louping
ill virus (LIV) in the United Kingdom, Ireland, Norway, Den-
mark, and Russia; and Powassan virus in the United States and
Canada. Upwards of 10,000 TBEV cases per year are reported,
with a trend for increased incidence in recent years and
emergence of the disease in new geographic regions (Beauté
et al., 2018; Girl et al., 2020; Kollaritsch et al., 2011; Morens
and Fauci, 2020; Smura et al., 2019; Süss et al., 2006; Yoshii,
2019; Zeman and Bene, 2004).
The bite of an infected tick, or the consumption of unpas-
teurized milk from infected animals, causes a biphasic illness,
which begins with a period of influenza-like symptoms followed
by the development of neurological disease (tick-borne en-
cephalitis [TBE]). There is no specific therapy for TBE, and
treatment is limited to supportive care. For those individuals
who survive, long-term sequelae are common (Bogovič et al.,
2018b; Caini et al., 2012; Cisak et al., 2010; Donoso-Mantke
et al., 2011; Holzmann, 2003; Holzmann et al., 2009; Kaiser,
2008).
Although TBEV vaccines are available, immunity requires
regular boosting, and vaccination is less effective in the young
and elderly. Vaccination requires administration of three sepa-
rate doses spaced over up to 2 yr, with booster doses recom-
mended at intervals of 3–5 yr (World Health Organization,
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irb.usi.ch; Daniel Růžek: ruzekd@paru.cas.cz; Pamela J. Bjorkman: bjorkman@caltech.edu.
© 2021 Agudelo et al. This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).
Rockefeller University Press https://doi.org/10.1084/jem.20210236 1 of 16








f Technology user on 15 April 2021
2019). Breakthrough TBEV infection occurs despite vaccination
(Dobler et al., 2020; Lotrič-Furlan et al., 2017).
Recovered individuals can produce potent serologic neutral-
izing activity against TBEV, and the serum can be cross-reactive
against other tick-borne flaviviruses, but the nature of the an-
tibodies that mediate these effects is not known (Calisher et al.,
1989; Mansfield et al., 2011). Postexposure prophylaxis with
hyperimmune plasma Ig from vaccinated donors provides pro-
tection if administered within 3 d of an infected tick bite (Kreil
et al., 1998; Pen’evskaia and Rudakov, 2010). However, this
practice was discontinued outside of Russia due to anecdotal
evidence of adverse events in children and the concern of pos-
sible antibody-dependent enhancement of disease (Halstead,
2014; Phillpotts et al., 1985; Ruzek et al., 2019).
Here, we report on the molecular properties of human
anti-TBEV antibodies with exceptional neutralizing potency
and breadth that are effective in protection and early ther-
apy in mice.
Results
Serological responses in a TBEV-infected cohort
We analyzed sera from 141 individuals hospitalized with TBE
during the 2011 and 2018 outbreaks in the Czech Republic (see
Materials and methods). Samples were obtained at the time of
hospitalization during the encephalitic phase of disease (Fig. 1 A;
Holzmann, 2003). In agreement with previous reports (Bogovič
et al., 2018a; Bogovic and Strle, 2015), the cohort was charac-
terized by higher incidence in males (61.1%) and older in-
dividuals (mean age, 49 yr; Table S1). Control sera were also
obtained from 168 randomly selected blood bank donors and 10
individuals vaccinated against TBEV (Table S1). All sera were
screened by ELISA at a dilution of 1:500 for the presence of IgG
antibodies binding to the EDIII of TBEV (Fig. 1 B). The signal in
infected individuals was significantly higher than in the vacci-
nated and blood donor groups (P = 0.0005 and P < 0.0001 by
ANOVA using Tukey’s correction, respectively; Fig. 1 B). There
was no correlation between TBEV EDIII ELISA reactivity and
age, duration of hospitalization, severity of infection, or gender
of patient, but serum EDIII binding did correlate positively with
patient IgM (P = 0.0029) and IgG (P < 0.0001) levels at the time
of hospitalization (Fig. S1, A–F).
To evaluate serum neutralizing activity, samples obtained
from recovered and vaccinated individuals were screened at a 1:
6 × 105 dilution for neutralization using luciferase-expressing
TBEV reporter virus particles (RVPs; see Materials and meth-
ods; Pierson et al., 2006). Neutralizing activity ranged from
complete to undetectable and was significantly lower in
vaccinees (P < 0.0001; Fig. 1 C). Neutralization correlated posi-
tively with patient IgM levels at the time of hospitalization (P <
0.0001) and EDIII binding in ELISA (P = 0.0004); otherwise,
there was no correlation with demographic or clinical data (Fig.
S1, G–M). The half-maximal neutralizing titers (NT50) for the top
28 infected individuals varied from 0.37 to 6.7 × 106 (Fig. 1, D and
E). In contrast, vaccinees showed NT50s of 0.32–1.0 × 104 (Fig. S1,
N and O). We conclude that individuals hospitalized for TBEV
infection show a broad distribution of EDIII binding and
neutralizing activity that is generally higher than the vaccinees
in this cohort.
B cell memory convergence on specific antibody genes
To characterize the anti-TBEV antibodies, we purified B cells
that bind to TBEV EDIII from peripheral blood of six infected
individuals (orange in Fig. 1, D and E) and three vaccinees (see
Materials and methods; Fig. 2, A–D; and Fig. S2 A). The fre-
quency of TBEV EDIII–specific B cells was higher in the infected
group (0.067–0.31%) compared with vaccinees (1.28 × 10−3–5.95
× 10−3%). In total, 776 IgG antibody heavy and light chain gene
pairs were amplified by RT-PCR and sequenced (see Materials
and methods; Fig. 2, B and D; and Table S2). The average somatic
hypermutation in Ig heavy and light chain genes (Ig variable
heavy gene [IGVH], Ig variable kappa gene [IVGK], and Ig var-
iable light gene [IGVL]) was 18 and 9 nt, respectively,
complementarity-determining region 3 (CDR3) length was
normal (mean CDRH3 length of 13.5 and mean CDRL3 length of
9.4), and hydrophobicity was slightly increased compared with
control (P < 0.0001; Fig. S2, B–D; Briney et al., 2019; Rock et al.,
1994). As with other viral pathogens, including HIV-1, Zika,
hepatitis B, and SARS-CoV-2 (Robbiani et al., 2017; Robbiani
et al., 2020; Scheid et al., 2011; Wang et al., 2020; West et al.,
2012), many of the sequences were found in expanded B cell
clones (37.9%; Fig. 2, B and D).
Sequence analysis revealed antibodies with similar features
within and between individuals (Fig. 2, B, D, and E; Table S2; and
Table S3). For example, VH1–69 and VH3–48 accounted for
59.2% and 7.5% of all clonal sequences, respectively (shades of
blue and red in Fig. 2, B and D). In addition, related sequences
containing these VH genes were found in multiple donors
(purple lines in Fig. 2 E). Usage of VH1–69, VH3–30, VK2–28,
VK1–33, and VL4–69 genes in infected donors was significantly
overrepresented (P < 0.01); VH3–48, VK1–5, and VL2–14 genes
were also enriched, although not significantly (Fig. S3, A–C). In
some cases, including clonally expanded IGVH1–69/Ig variable
kappa gene 2–28 (IGVK2–28) and IGVH3–48/IGVK1–5 anti-
bodies, sequence similarities between individual donors ex-
tended to the IGH and IGL CDR3s (Fig. S2, D and E; and Table S3).
We conclude that the memory B cell response to the TBEV EDIII
converges toward specific antibody genes.
Potent and broadly cross-reactive anti-TBEV antibodies
59 antibodies (46 from convalescent and 13 from vaccinated
donors; Table S4) were cloned, recombinantly expressed, and
tested in ELISA for binding to EDIII proteins corresponding to all
three TBEV subtypes: Western European (TBEVWE), Far Eastern
(TBEVFE), and Siberian (TBEVSi; Fig. 3 A, Fig. S4 A, and Table
S5). All but 1 of the 59 antibodies bound to all three EDIIIs with
similar half-maximal effective concentrations (EC50) ranging
from 0.2 to 12 ng/ml (Fig. 3 B and Table S5).
When tested for neutralizing activity, 43 out of 46 antibodies
obtained from infected donors neutralized TBEV RVPswith half-
maximal inhibitory concentrations (IC50s) as low as 0.02 ng/ml
(Fig. 3, C and D; and Table S5). In contrast, the best antibody
obtained from vaccinated donors was over two orders of mag-
nitude less potent (IC50 of 8.3 ng/ml). Seven antibodies, all
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isolated from infected donors, were potent neutralizers of TBEV
RVPs with IC50s below 1 ng/ml (Fig. 3 D). Four of these anti-
bodies were also evaluated for neutralization of authentic TBEV
(Fig. 3, E and F). All four antibodies showed potent activity, with
IC50s ranging from 35.9 to 268.8 ng/ml (Table S5).
To determine whether the TBEV antibodies cross-react with
related viruses, we screened them at a single concentration
(1 µg/ml) for binding to the EDIIIs of Langat virus (LGTV), LIV,
OHFV, KFDV, and Powassan lineage I and II viruses (Powassan-
LB virus [POWV-LB] and Powassan deer tick virus [POWV-
DTV]; see Materials and methods and Fig. S4, B and C). Broad
cross-reactivity was observed for many of the antibodies tested
(Fig. S4, B and C). To determine whether the antibodies are also
broadly neutralizing, we screened them against RVPs corre-
sponding to the same panel of tick-borne viruses. When tested at
a concentration of 1 µg/ml, most of the IGHV1–69 antibodies
neutralized LGTV, LIV, POWV-LB, and POWV-DTV, and one of
the IGVH3–48/IGVK1–5 antibodies neutralized all RVPs except
POWV-LB (Fig. S4, B and C). IC50s against the flavivirus RVP
panel were <10 ng/ml for several of the cross-reactive antibodies
(Fig. 3 G; Fig. S4, D–I; and Table S5). For example, an IGVH3–48/
IGVK1–5 antibody, T056, is a potent neutralizer of LGTV, LIV,
and OHFV, with IC50 values ≤1 ng/ml. We conclude that some
TBEV neutralizing antibodies are broadly active against tick-
borne flaviviruses.
Antibody T025 binds to the EDIII lateral ridge
To gain insights into the mechanism of neutralization by human
anti-TBEV antibodies, we solved crystal structures of the
antigen-binding fragment (Fab) from the broad and potent an-
tibody T025 (IGVH3–30/IGVK3–15) in complex with the EDIII
domains of all three subtypes of TBEV (Fig. 4, Fig. S5, and Table
S6). The structure of the T025 Fab–TBEVWE EDIII complex re-
vealed that the antibody binds the lateral ridge of EDIII in the
proximity of the EDI–EDIII hinge region, making both heavy
chain (HC) and light chain (LC) contacts to the EDI–EDIII hinge
and the BC loop and light chain contacts to the DE loop of the
EDIII (Fig. 4 A). The antibody contacts EDIII using CDRH2,
CDRH3, CDRL1, and CDRL3, and buries 598 Å2 of surface area on
the EDIII (333 Å2 by the VH and 265 Å2 by the VL). T025 inserts
Figure 1. Screening individuals for TBEV antibodies. (A) Diagrammatic representation of the clinical course of TBE. The approximate time of serum
collection is shown in yellow. (B) TBEV EDIII IgG ELISA. Graph shows optical density measurement (y axis) relative to a negative control serum for samples from
141 TBEV-infected individuals, 10 TBEV vaccinees, and 168 random blood donors (1:500 dilution) measured in singlicate. P = 0.0005 for infected versus
vaccinees; P < 0.0001 for infected versus blood donors; P = 0.0003 for vaccinees versus blood donors; calculated by one-way ANOVA followed by Tukey’s test.
Horizontal lines indicate the mean. (C) TBEV RVP neutralization screening. Graph shows ranked serum neutralizing activity (1:600,000 dilution) against TBEV
RVPs (average of duplicate wells) relative to no serum control. The orange box (bottom right) indicates the 28 best neutralizers of 141 TBEV-infected individuals
and 10 TBEV vaccinees tested. P < 0.0001; calculated using two-tailed Mann–Whitney test. (D) TBEV RVP neutralization curves. Plot shows representative
neutralization curves for each of the 28 most potent sera from C. Representative of two experiments, each performed in triplicate. Error bars indicate standard
deviation. (E) Ranked NT50s for the top 28 individuals. Average of two independent experiments. In D and E, orange indicates the donors of PBMCs for antibody
cloning. Related to Fig. S1 and Table S1. RLU, relative light units.
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Asp100HC and Trp94LC into a cleft in the EDIII, making a salt
bridge (Asp100HC–Lys311EDIII) and hydrogen bonds to the EDIII
(Fig. 4 B). Crystal structures of T025 Fab in complex with
TBEVFE EDIII and TBEVSi EDIII were similar to the T025-
TBEVWE EDIII structure (root-mean-square deviations [RMSDs]
= 0.54 Å for 518 Cα atoms and 0.26 Å for 525 Cα atoms, re-
spectively), consistent with 100% sequence conservation be-
tween these three strains of virus in the EDIII epitope residues
(Fig. S5).
We compared the T025 Fab–TBEVWE structure to a 3.9 Å
cryo-EM structure of a mouse monoclonal antibody (19/1786)
bound to the TBEV virion (Füzik et al., 2018). T025 and 19/1786
are related by <65% amino acid sequence identity in the VHVL
and 47% in the CDRs, but structural alignment of the structures
by the Cα atoms of the EDIIIs shows that the two antibodies
recognize similar epitopes (Fig. 4 C) and adopt similar poses
(Fig. 4 D). We can therefore use the lower-resolution cryo-EM
structure to deduce details about how T025 binds to and neu-
tralizes the virus. In addition to contacts with EDIII, 19/1786
interacts with either the EDI or EDII of a neighboring subunit
(Füzik et al., 2018). This, taken together with the relatively low
buried surface area on the EDIII by T025 (∼600 Å2 compared
with a typical value of ∼1,100 Å2; Ramaraj et al., 2012), suggests
that T025 also contacts neighboring domains on a native virion.
It is also likely that, in common with recognition of virions by
19/1786, 120 of the 180 EDIIIs on the virion could be bound
by T025.
Antibody T025 prevents and treats infection in mice
To determine whether anti-EDIII antibodies can protect against
infection in vivo, we performed prophylaxis experiments in
BALB/c mice. The mice received graded doses of T025 (100–0.1
µg per mouse) 24 h before challenge with 102 PFU TBEV (a lethal
dose). All mice treated with the isotype control antibody died by
day 10 (n = 6). In contrast, even the lowest dose of T025 was
protective; all but 1 of the 24 mice receiving the antibody sur-
vived (P < 0.0001; Fig. 5 A). To test T025’s potential for therapy,
BALB/c mice were infected with 102 PFU TBEV and then injected
with 30 µg T025 or isotype control 1, 3, or 5 d later (Fig. 5 B). All
12 control mice succumbed to the infection by day 13. In contrast,
Figure 2. Anti-TBEV antibodies from infected and vaccinated individuals. (A) Identification of TBEV-specific B cells from infected donors. Representative
flow cytometry plots showing B cells binding to AF647- and PE-labeled TBEV EDIII in one control and six TBEV-infected donors. Numbers indicate percentage
of double-positive B cells. The gating strategy is shown in Fig. S2 A. (B) Clonal analysis of antibody sequences. Pie charts show the distribution of antibody
sequences from infected donors. The number in the center represents the total number of antibody sequences obtained. Colored or gray pie slices correspond
to clonally related sequences, with the size of the slice proportional to the number of sequences. All blue slices are IGVH1–69, and all red slices are IGVH3–48/
IGVK1–5. White slices correspond to antibody sequences that are not part of a clone (singlets). (C and D) Same as in A and B, but for one healthy control and
three vaccinated donors. (E) Antibody sequence relatedness. Circos plot shows sequences from all donors, with color-coding as in B and D. Connecting lines
indicate antibodies that share IGH and IGL V and J genes. Purple, green, and gray lines connect related clones to each other, clones to singlets, and singlets to
singlets, respectively. Related to Figs. S2 and S3, Table S2, and Table S3.
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Figure 3. Identification of potent and broadly cross-reactive monoclonal antibodies. (A) TBEVWE EDIII ELISA binding curves for 46 and 13 monoclonals
from infected and vaccinated individuals, respectively. Data are representative of two experiments performed in singlicate. Dotted line is 10–1074 isotype
control. (B) Dot plot summarizing average EC50 values for the antibodies in A to each of three TBEV subtype EDIIIs: TBEVWE, TBEVFE, and TBEVSi. Average of
two experiments. The horizontal lines indicate themean value. (C) RVP neutralization curves for the antibodies in A normalized to no antibody control. Data are
representative of two experiments, each performed in triplicate. Error bars indicate standard deviation. (D) Dot plot summarizing the average IC50 for TBEVWE
RVP neutralization by the antibodies as in C. Horizontal line indicates the mean IC50. No statistical difference was found by two-tailed Mann–Whitney test.
(E and F) TBEV neutralization in vitro. In E, curves represent virus neutralization by serially diluted antibodies. Representative of two independent experiments
performed in octuplicate. In F, representative immunofluorescence microscopy images of PS cells infected in the presence of the indicated antibodies are
shown. Green is viral antigen, and blue is cell nuclei. Scale bar indicates 200 µm. (G) Cross-neutralization by anti-TBEV antibodies. Graph shows IC50s for
selected antibodies against RVPs corresponding to POWV-LB, POWV-DTV, KFDV, LGTV, LIV, and OHFV. Average of two independent experiments performed in
triplicate. Horizontal line indicates the mean IC50. In A–D and G, blue and red indicate infected donor-derived IGVH1–69/kappa and IGVH3-48/IGVK1–5 an-
tibodies, while purple indicates IGHV1–69/kappa antibodies from vaccinated individuals. Antibody T025 is shown in orange. In B, D, and G, circles and triangles
correspond to antibodies derived from infected or vaccinated donors, respectively. Related to Fig. S4, Table S4, and Table S5.
Agudelo et al. Journal of Experimental Medicine 5 of 16








f Technology user on 15 April 2021
12 out of 13 mice treated with T025 on day 1 and 4 out of 13 mice
treated on day 3 after infection survived. All mice treated with
T025 5 d after infection failed to respond. Thus T025, a broadly
neutralizing human anti-TBEV antibody, is efficacious in pre-
vention and early treatment of TBEV infection in BALB/c mice.
Discussion
Tick-borne flaviviruses can cause a fulminant encephalitis for
which there is no effective therapy. This group of viruses are a
growing public health concern in Europe, Asia, and North
America. Among disease-causing tick-borne flaviviruses, TBEV
is prevalent in Central Europe and Russia. Although there is a
great deal of information on the polyclonal humoral immune
response to TBEV (Albinsson et al., 2018; Holzmann, 2003;
Matveeva et al., 1995; McAuley et al., 2017; Remoli et al., 2015),
there is little or no understanding of the molecular nature of the
neutralizing antibody response induced by natural infection or
vaccination. We report on 776 antibodies obtained frommemory
B cells of six recovered and three vaccinated individuals, among
which are several broad and potent neutralizers of tick-borne
flaviviruses. The data provide insights into the human antibody
response to TBEV and related pathogens, as well as mechanisms
of antibody-induced neutralization. Finally, broad and potent
neutralizing human monoclonal antibodies are highly effective
for protection and therapy in vivo and have significant potential
for clinical use.
Human neutralizing antibody responses to pathogens fre-
quently converge on the same IGV genes. Examples include
neutralizing antibodies to HIV-1, influenza, Zika, hepatitis B,
and SARS-CoV-2 viruses (Robbiani et al., 2017; Robbiani et al.,
2020; Scheid et al., 2011; Tiller et al., 2007; Wang et al., 2020;
West et al., 2012). Antibodies to the EDIII of TBEV produced by
different individuals show strong homology that, like SARS-
CoV-2 antibodies, extends beyond IGV heavy and light chain
gene pairing and includes the CDR3 regions.
Figure 4. T025 antibody recognizes a lateral ridge epitope on TBEV EDIII that is exposed on the mature virus structure. (A) T025 recognition of the
TBEVWE EDIII. T025 interacts with the N-terminal region (EDI–EDIII hinge, the BC loop, and the DE loop) on TBEVWE EDIII. (B) T025 epitope. TBEVWE EDIII
residues with an atom within 4 Å of a residue in the T025 Fab are highlighted on a surface representation of the EDIII antigen. CDRH3 and CDRL3 are shown as
ribbon backbone with stick side chains. (C) T025 recognizes a similar epitope as the anti-TBEV mouse antibody 19/1786. The T025 epitope is shown in shades
of orange; the 19/1786 epitope is outlined in a blue dashed line. Residues within the 19/1786 epitope, but not in the T025 epitope, are labeled. Epitopes are
defined as residues that contain an atom within 4 Å of an atom in a residue on the antibody. (D) Surface representation of the cryo-EM structure of TBEV (PDB
accession no. 5O6A) shown with fivefold, threefold, and twofold icosahedral symmetry operators at select vertices (left) with inset comparing binding poses of
T025 and 19/1786 antibodies (right). Inset: Close-up of the indicated portion (dotted box) of the cryo-EM structure of the viral surface interacting with the 19/
1786 VHVL domains (PDB accession no. 5O6V) with the E domains labeled in red, yellow, and blue and the VHVL domains in teal and cyan. The T025-TBEVWE
EDIII crystal structure was docked onto a virion EDIII adjacent to an icosahedral twofold symmetry axis after alignment of the EDIII domains (RMSD = 0.97 Å, 82
Ca atoms). The T025 VHVL binds EDIII with a similar pose as the 19/1786 VHVL. Related to Fig. S5 and Table S6.
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Among the neutralizing antibodies to TBEV, VH1–69 and
VH3–48 were recurrent in multiple donors. VH1–69 was paired
with a variety of light chain genes to produce neutralizing
antibodies that were found among vaccinees and recovered in-
dividuals. This group of antibodies varied broadly in neutraliz-
ing activity with IC50s ranging from 12–1,180 ng/ml (geometric
mean, 186.2 ng/ml). VH1–69 antibodies are highly represented in
the human repertoire and are also common among broadly
neutralizing antibodies to influenza, hepatitis C, and HIV-1 vi-
ruses (Chen et al., 2019). Anti-TBEV VH3–48 antibodies differed
from VH1–69 in that they were always paired with the same
light chain, VK1–5. VH3–48 antibodies were also more potent
than VH1–69, with IC50s ranging from 0.5 to 7.3 ng/ml (geo-
metric mean, 2 ng/ml), and they were only found in
Figure 5. Prevention and therapy with T025.
(A) T025 is efficacious in preexposure prophy-
laxis. Mice were treated with T025 or 10–1074
(isotype control) 24 h before infection with a
lethal dose of TBEV-Hypr. Top: Histogram shows
disease score over time. Antibody dose is indi-
cated on the right. Two independent experi-
ments were combined, with three mice per
group. Bottom: Kaplan–Meier survival curve. The
P value was calculated with the Mantel–Cox test
(P < 0.0001). (B) T025 protects mice when ad-
ministered after infection. Mice were treated
with 30 µg T025 or control 10–1074 at 1, 3, or
5 d post infection (DPI). Three experiments
were combined, with six or seven mice per
group; P < 0.0001 for +1 DPI, P = 0.0368 for
+3 DPI, and no significant difference for +5
DPI by Mantel–Cox test.
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convalescent individuals. The absence of this class of potent
antibodies in the vaccinees examined is consistent with the
lower levels of serum neutralizing potency in this group. Finally,
VH3–48 antibodies are also potent neutralizers of several related
tick-borne flaviviruses including KFDV, LGTV, LIV, and OHFV,
with IC50s of 1–36 ng/ml.
Antibodies to a number of different flaviviruses, including
dengue and Zika virus, can be protective if administered before
and even after infection (Robbiani et al., 2017; Xu et al., 2017). In
Russia and Kazakhstan, administration of TBEV hyperimmune
plasma Ig is recommended for postexposure prophylaxis for
individuals that present within 3 d of a tick bite (Pen’evskaia and
Rudakov, 2010; Russian Ministry of Health, 2008). The efficacy
of this intervention may vary from batch to batch of donor
plasma Ig (Rabel et al., 2012; Ruzek et al., 2019), and its use was
discontinued in some countries after a small number of adverse
events and concerns about the possibility of antibody-dependent
enhancement of disease (Arras et al., 1996; Kluger et al., 1995;
Waldvogel et al., 1996). Mouse monoclonal antibodies can also
protect against TBEV but have not been tested in the clinic
(Baykov et al., 2014; Levanov et al., 2010; Matveev et al., 2020).
Our experiments extend previous work by uncovering human
monoclonal antibodies that prevent infection in mice even when
administered at doses as low as ∼0.005 mg/kg. Notably, these
antibodies also suppress disease in mice, even when adminis-
tered 3 d after infection at a dose of ∼1.5 mg/kg.
Antibodies against EDIII are often among the most potent
raised during flavivirus infection (Beasley and Barrett, 2002;
Beltramello et al., 2010; Crill and Roehrig, 2001; Screaton et al.,
2015; Sun et al., 2017). The broad and potent anti-TBEV antibody
T025 recognizes a lateral ridge epitope on EDIII that is also
targeted by antibodies raised against other flaviviruses (Edeling
et al., 2014; Füzik et al., 2018; Nybakken et al., 2005; Renner
et al., 2018; Robbiani et al., 2017; Zhao et al., 2020). Several
human antibodies against the lateral ridge of EDIII have been
previously characterized, including Z021 isolated from a con-
valescent Zika donor, which recognizes a similar epitope and has
an angle of approach similar to T025 (Keeffe et al., 2018). These
results suggest a common mechanism for potent neutralization
of flaviviruses. Targeting this epitope likely interferes with the
structural rearrangement necessary for fusion, preventing in-
fection (Füzik et al., 2018; Nybakken et al., 2005; Renner et al.,
2018; Thompson et al., 2009). Although anti-EDIII antibodies
can be potently neutralizing, antibodies against the EDIII in
humans constitute only a small fraction of the immune response
(Beltramello et al., 2010; Lai et al., 2008; Wahala et al., 2009),
suggesting that a targeted vaccine strategy focusing on EDIII
could be beneficial.
While most antibodies to flavivirus EDIII are thought to be
virus specific (Crill and Roehrig, 2001; Pierson et al., 2008;
Roehrig, 2003; Stettler et al., 2016), T025 is a potent neutralizer
of not only TBEV but also several other tick-borne flaviviruses.
The pairwise sequence identity of the EDIII epitope of TBEV to
predicted epitopes in LGTV, LIV, and OHMV EDIIIs is high
(differences of 1–2 amino acids), and the residues that differ
have similar biochemical properties (e.g., threonine to serine).
The exception is KFDV, which is sensitive to T025 but differs in
sequence to TBEV in the T025 epitope on the EDIII. Contacts
made outside of the EDIII may also contribute to the sensitivity
of KDFV to T025. Powassan virus contains an amino acid in-
sertion in the BC loop of the EDIII compared with the TBEV
EDIII, which likely prevents binding of T025 and therefore is
insensitive to T025 neutralization.
Available TBEV vaccines were developed over 30 yr ago and
consist of inactivated virus grown on chick embryo cells. Vac-
cination is TBEV specific, requires priming and two boosts, and
results in 90–100% seroconversion depending on the vaccine
used (Loew-Baselli et al., 2009; Maikova et al., 2019; Vorovitch
et al., 2019). Additional boosts are recommended every 3–5 yr
for the lifetime of the individual. The existence of broad and
potent VH3–48 antibodies suggests that next-generation vac-
cines specifically designed to target the epitope recognized by
these antibodies might be universally effective against TBEV,
KFDV, LGTV, LIV, and OHFV. Finally, potent human antibodies
with broad activity against tick-borne flaviviruses have signif-
icant potential for clinical use in individuals who are at high risk
and do not respond to the vaccine, as well as for therapy in the
early stages of infection.
Materials and methods
Human subjects and clinical information
Samples of peripheral blood were obtained upon consent from
individuals previously hospitalized with confirmed TBEV in-
fection or individuals previously vaccinated against TBEV in
České Budějovice, Czech Republic, under protocols approved by
the ethical committees of the Hospital in České Budějovice
(approval no. 103/19), the Biology Center of the Czech Academy
of Sciences (approval no. 1/2018), and The Rockefeller Univer-
sity (IRB DRO-0984). Clinical data were obtained at the treating
hospital, and severity of disease was evaluated according to the
following scale: mild, flu-like symptoms with meningeal irrita-
tion defined as meningitis, characterized by fever, fatigue,
nausea, headache, back pain, arthralgia/myalgia and neck or
back stiffness; moderate, previous symptoms together with
tremor, vertigo, somnolence, and photophobia defined as me-
ningoencephalitis; severe, prolonged neurological consequences
including ataxia, titubation, altered mental status, memory loss,
quantitative disturbance of consciousness, and palsy revealed as
encephalitis, encephalomyelitis, or encephalomyeloradiculitis
(Bogovic and Strle, 2015; Ruzek et al., 2019).
Blood samples processing and storage
Peripheral blood mononuclear cells (PBMCs) were obtained by
gradient centrifugation using Ficoll and stored in liquid nitrogen
in freezing media (90% FCS and 10% DMSO). Prior to experi-
ments, aliquots of sera (from infected, vaccinated, and random
blood bank donors) were heat-inactivated at 56°C for 1 h and
then stored at 4°C.
Protein expression and purification
EDIII antigens were expressed in Escherichia coli and purified
from inclusion bodies as previously reported (Robbiani et al.,
2017; Sapparapu et al., 2016). Expression vectors containing
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codon-optimized sequences encoding residues 299–397 for TBEV
strain Neudoerfl (TBEVWE; NC_001672.1) or 301–397 for strains
Sofjin (TBEVFE; UniProtKB accession no. P07720) and Va-
silchenko (TBEVSi; AF069066) were used to produce untagged
EDIII proteins or EDIII proteins containing a C-terminal 6XHis-
Avitag. Constructs encoding untagged EDIIIs of other tick-borne
flaviviruses were constructed similarly (POWV strain LB, Gen-
Bank accession nos. L06436.1; POWV isolate DTV, HM440561.1;
KFDV strain W-377, JF416960.1; LGTV strain TP21-636, NC_
003690.1; LIV isolate LI3/1, KP144331.1; OHFV strain Bogolu-
vovska, NC_005062). Expression plasmids were transformed into
BL21(DE3) E. coli and induced with 1 mM isopropyl β-D-1-thio-
galactopyranoside at 37°C for 4 h. The cells were lysed and the in-
soluble fraction containing inclusion bodies was solubilized and
refolded in 400 mM L-arginine, 100 mM Tris-base, pH 8.0, 2 mM
EDTA, 0.2 mM phenyl-methylsulfonyl fluoride, 5 mM reduced and
0.5 mM oxidized glutathione, and 10% glycerol at 4°C. Refolded
protein was purified by size exclusion chromatography (Cytiva;
Superdex 75) in 20 mM Tris, pH 8.0, 150 mM NaCl, and 0.02%
NaN3. EDIIIs were concentrated to 10–20 mg/ml.
T025 Fabs for structural studies were produced and purified
as described in previous studies (Keeffe et al., 2018; Robbiani
et al., 2017; Robbiani et al., 2020;Wang et al., 2020). Briefly, Fabs
containing a 6XHis purification tag at the C terminus of the HC
were expressed by transiently transfecting Expi293 cells (Life
Technologies) with appropriate heavy and light chain plasmids.
His-tagged Fabs were purified from expression supernatants
using Ni-nitrilotriacetic acid affinity chromatography (Cytiva)
followed by size exclusion chromatography (Cytiva; Superdex
200) in 20 mM Tris, pH 8.0, 150 mM NaCl, and 0.02% NaN3.
Fabs were concentrated to ∼15 mg/ml.
Sequence analysis
Antibody sequences were analyzed as described previously
(Robbiani et al., 2020); briefly, sequences were trimmed and
annotated using Igblastn v.1.14.0 (Ye et al., 2013) and Change-O
toolkit v.0.4.5 (Gupta et al., 2015). Sequences from the same cell
were paired and assigned clonotypes based on V and J genes
using in-house R and Perl scripts (available on GitHub; https://
github.com/stratust/igpipeline). Nucleotide somatic hyper-
mutation and CDR3 length were also analyzed using in-house R
and Perl scripts, as described previously (Robbiani et al., 2020);
hypermutation analysis was based on the closest germlines in
Igblastn. Hydrophobicity GRAVY (grand average of hydropathy)
scores were calculated using Guy H.R. Hydrophobicity scale
(Guy, 1985; Kyte and Doolittle, 1982) and R package Peptides
(https://journal.r-project.org/archive/2015/RJ-2015-001/RJ-
2015-001.pdf), based on 776 IGH CDR3 sequences from this study
and 22,654,256 IGH CDR3 sequences from public databases of
memory B cell receptor sequences (DeWitt et al., 2016). Distri-
bution was determined using the Shapiro–Wilk test with all
CDR3 sequence GRAVY scores from this study and 5,000 ran-
domly selected GRAVY scores from the public database. The
Wilcoxon nonparametric test was used to test for significant
difference in hydrophobicity.
Frequency distributions of V genes in anti-TBEV antibodies
from six infected donors were compared with Sequence Read
Archive accession no. SRP010970 (https://trace.ncbi.nlm.nih.
gov/Traces/sra/?study=SRP010970; Rubelt et al., 2012). V gene
assignments were based on the above-described analysis, and
frequencies were calculated for six infected donors using se-
quences with unique CDR3s. Statistical significance was deter-
mined using two-tailed t tests with unequal variances. Sequence
logos were generated from left-aligned CDR3 sequences from
each antibody set using WebLogo (Crooks et al., 2004).
Protein biotinylation
Avi-tagged TBEVFE EDIII was biotinylated using the Biotin-
Protein Ligase BIRA kit according to the manufacturer’s
instructions (Avidity) and conjugated to streptavidin-PE
(BD Biosciences; 554061) and streptavidin-Alexa Fluor 647
(BioLegend; 405237). Ovalbumin (Sigma-Aldrich; A5503-1G)
was biotinylated using the EZ Sulfo-NHS-LC-Biotinylation kit
according to the manufacturer’s instructions (Thermo Fisher
Scientific; A39257) and conjugated to streptavidin BV711 (BD
Biosciences; 563262). Biotinylation was confirmed by ELISA
before use in flow cytometry.
Single-cell sorting
PBMCs from sample 111 were enriched for B cells via positive
selection using CD19microbeads (Miltenyi Biotec; 130–050-301).
PBMCs from all other donors were enriched for B cells by neg-
ative selection (Miltenyi Biotec; 130–101-638). All selection
protocols were performed according to the manufacturer’s in-
structions. Enriched B cells were incubated for 30 min on ice in
FACS buffer (1× PBS, 2% calf serum, 1 mM EDTA) with
fluorophore-labeled EDIII and ovalbumin, and in the presence of
anti-human antibodies anti-CD3-APC-eFluro 780 (Invitrogen;
47–0037-41), anti-CD8-APC-eFluro 780 (Invitrogen; 47–0086-
42), anti-CD14-APC-eFluro 780 (Invitrogen; 47–0149-42), anti-
CD16-APC-eFluro 780 (Invitrogen; 47–0168-41), anti-CD20-PECy7 (BD
Biosciences; 335793), and Zombie NIR (BioLegend; 423105). Single
CD3−CD8−CD14−CD16−ZombieNIR−CD20+Ova−EDIII-PE+EDIII-AF647+
B cells were sorted using a FACS Aria III (Becton Dickinson) into in-
dividual wells of 96-well plates. Each well contained 4 µl of a lysis
buffer comprising 0.5× PBS, 10 mM DTT, and 3,000 U/ml RNasin
Ribonuclease Inhibitors (Promega; N2615). Sorted cells were snap-
frozen on dry ice and then stored at −80°C. Antibody sequences are
derived frommemoryB cells because they originate fromsmall CD20+
cells, and the antibody genes were PCR amplified using IgG-specific
primers.
Antibody sequencing, cloning, and expression
RNA from single cells was reverse transcribed using SuperScript
III Reverse transcription (Invitrogen; 18080–044). The resulting
cDNA was stored at −20°C until amplification of the variable
Ig heavy (IGH), Ig light (IGL), and Ig kappa (IGK) genes by
nested PCR followed by Sanger sequencing. Amplicons from
the first PCR reaction were used as template for nested PCR-
amplification followed by sequence- and ligation-independent
cloning into antibody expression vectors as previously de-
scribed (Robbiani et al., 2020). Recombinant monoclonal anti-
bodies were produced and purified as previously detailed (Klein
et al., 2014).
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Plasmids for the production of RVP
A West Nile virus subgenomic replicon-expressing plasmid en-
coding Renilla luciferase (pWNVII-Rep-REN-IB) and a ZIKV
CprME expression plasmid had previously been obtained from
Ted Pierson (National Institutes of Health, Bethesda, MD;
Pierson et al., 2006; Robbiani et al., 2017). The ZIKV CprME
expression plasmid was manipulated by restriction enzyme di-
gestion and ligation to express the CprME of other flaviviruses
as follows.
TBEV
Synthetic DNA with CprME coding sequence (flanked at the 59
by the polylinker and Kozak sequence 59-GGAATTCGCGGCCGC
CTCAGG-39 and at the 39 by the stop codons and polylinker 59-
TAATAGTTAATTAACTCGAGCCGCGG-39; “CprME flanked”)
corresponding to TBEV, Western European subtype strain
Neudoerfl (GenBank accession no. NC_001672), was amplified
with primers DFRp1532 (59-GGAATTCGCGGCCGCCTCAGG-39)
and DFRp1533 (59-GCGGCTCGAGTTAATTAA-39) before cloning
at the NotI and PacI sites of plasmid pPOWV-LB-CprME (see
below), resulting in pTBEV-WE-CprME.
POWV-LB
Synthetic DNA containing the CprME sequence (underlined) of
POWV-LB strain (GenBank accession no. L06436.1 with six


































































AGCCT-39) was PCR amplified with primers DFRp1511 (59-ATC
TACGTATTAGTCATCGCTATTA-39) and DFRp1514 (59-ACCGCG
GCTCGAGTTAATTAA-39) and cloned at the Eco105I and SacII
sites of plasmid pZIKV-HPF-CprME (Pierson et al., 2006;
Robbiani et al., 2017), resulting in pPOWV-LB-CprME.
POWV-DTV
A three-piece assembly PCR strategy was used. DNA upstream of
the CMV promoter in pZIKV-HFP-CprME to just downstream of
the beginning of the C-encoding region was PCR amplified with
primers RU-O-24611 (59-CTTGACCGACAATTGCATGAAG-39)
and RU-O-26690 (59-CTTTCCTTTAGAAGTAGTCACCATAGC
CTGCTTTTTTGTACAAAC-39), resulting in a fragment fusing the
CMV promoter with POWV-DTV C-encoding sequences (bolded
in primer RU-O-26690). Using as template DTVp1 (Kenney et al.,
2018), kindly provided by Aaron Brault (Centers for Disease
Control and Prevention, Fort Collins, CO) and based on the
Spooner strain of DTV, a fragment overlapping with the CMV
promoter–DTV C fusion to the region just downstream of a SacII
site within DTV genome was generated by PCR using oligos RU-
O-26689 (59-GTTTGTACAAAAAAGCAGGCTATGGTGACTACT
TCTAAAGGAAAG-39) and RU-O-26711 (59-GTTTCCCCATCCT
CTATCGCTCTG-39), with bolded nucleotides indicating
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synonymous mutations introduced to ablate the SacII site. DNA
was amplified using DTVp1 as template and oligos RU-O-26710
(59-CAGAGCGATAGAGGATGGGGAAAC-39; bolded nucleotides
indicate synonymous mutations) and RU-O-26688 (59-TTCGAA
CCGCGGCTGGGTCCTATTATGCTCCGACTCCCATTGTCATCAT
C-39) to generate a fragment overlapping the killed SacII site to
the end of the E protein coding region followed by a SacII site.
The three DNA fragments were annealed, extended and then
PCR amplified using primers RU-O-24611 and RU-O-26688. The
resulting DNA fragment was digested with SnaBI and SacII and
cloned into similarly digested pZIKV-HPF-CprME to generate
pPOWV-DTV-CprME.
KFDV
Synthetic DNA with the CprME-flanked sequence of KFDV,
strain W-377 (GenBank accession no. JF416960.1), was amplified
with primers DFRp1532 and DFRp1533 before cloning at the NotI
and PacI sites of plasmid pPOWV-LB-CprME (see above), re-
sulting in pKFDV-W-377-CprME.
LGTV
The CprME of LGTV, isolate TP21-636, was amplified from a
plasmid kindly provided by Dr. Sonja Best (Rocky Mountain
Laboratories of National Institutes of Health/National Institute
of Allergy and Infectious Diseases, Hamilton, MT) with primers
DFRp1563 (59-GGAATTCGCGGCCGCCTCAGGATGGCCGGGAAG
GCCGTTCTA-39) and DFRp1566 (59-CCGCGGCTCGAGTTAATT
AACTATTAGGCTCCAACCCCCAGAGTCAT-39) before cloning at
the NotI and PacI sites of plasmid pPOWV-LB-CprME, resulting
in pLGTV-TP21-636-CprME. There are two nucleotidemutations
from GenBank accession no. NC_003690 (A590G and A1893C).
LIV
Synthetic DNA with the CprME-flanked sequence of LIV, isolate
LI3/1 (GenBank accession no. KP144331), was amplified with
primers DFRp1532 and DFRp1533 before cloning at the NotI and
PacI sites of plasmid pPOWV-LB-CprME, resulting in pLIV-LI3/
1-CprME.
OHFV
Synthetic DNA with the CprME-flanked sequence of OHFV,
strain Bogoluvovska (GenBank accession no. NC_005062), was
amplified with primers DFRp1532 and DFRp1533 before cloning
at the NotI and PacI sites of plasmid pPOWV-LB-CprME, re-
sulting in pOHFV-CprME.
To confirm the absence of PCR-induced errors, all PCR-
derived regions were sequenced in the final plasmids.
RVP production
RVPs were produced by cotransfecting 1 µg pWNVII-Rep-RE-
N-IB plasmid with 3 µg of the flavivirus CprME plasmid of
choice into the permissive cell line Lenti-X 293T using Lip-
ofectamine 2000 (Invitrogen; 1166803) according to the manu-
facturer’s instructions. Cells were seeded 24 h previously at 106
cells/well in collagen-coated 6-well plates. Following transfec-
tion and 6 h incubation at 37°C, excess DNA–lipid complexes
were removed by aspiration and themedia replacedwith DMEM
(Gibco) containing 20mMHepes and 10% FBS. For the next 72 h,
in 24-h intervals, RVP-containing supernatants were harvested
and filtered through a 0.45-μm filter and frozen at −80°C, and
media were replaced with DMEM containing 20 mM Hepes and
10% FBS. Frozen RVPswere later thawed and titrated onHuh-7.5
cells to determine the dilution of RVPs at which cells express 106
relative light units in the absence of sera or antibody.
RVP neutralization assays
96-well plates were seeded with 7,500 Huh-7.5 cells/well in
50 µl DMEM (Gibco) supplemented with 10% FBS and 1% non-
essential amino acids. After 24 h, 100 µl diluted RVPs were
combined with 100 µl diluted sera or antibody, incubated for 1 h
at 37°C, and then 50 µl of the mix were added in triplicate to the
plated cells. RVPs are diluted appropriately in BA-1 diluent
(Medium 199 [Lonza] supplemented with 1% BSA and 100 units/
ml penicillin/streptomycin) to achieve the desired relative light
unit expression. After an additional 24 h of incubation at 37°C,
media was aspirated off the cells, replaced with 35 µl lysis buffer
(Promega; E2810), and the plates were frozen at −80°C. 15 µl of
the subsequently thawed lysis buffer was used for Renilla lu-
ciferase expression measurement using the Renilla Luciferase
Assay System (Promega; E2810). Sera were either diluted to 1:
600,000 final concentration for TBEV RVP neutralization
screening or serially diluted to generate curves. Recombinant
monoclonal antibodies were used at 10 µg/ml final concentra-
tion and serially diluted 1:3 for neutralization assays. NT50 and
IC50 were determined by nonlinear regression analysis using
Prism software (GraphPad). In the cross-neutralization screen-
ing against the panel of flavivirus RVPs, recombinant antibodies
were assayed at 1 µg/ml final concentration using the protocol
described above, and the results were compared with no anti-
body control.
ELISA assays
Binding of serum IgG or recombinant IgG antibodies to EDIII
proteins was measured by standard ELISA. High-binding 96-
well plates (Costar; 07–200-721) were coated overnight with
250 ng of the EDIII protein in PBS per well at room temperature;
plates were then blocked with 0.1 mM EDTA, 0.05% Tween, and
2% BSA in PBS for 2 h at room temperature. Samples were di-
luted in PBS-T, added to plates, and incubated for an additional
1 h at room temperature. Secondary goat anti-human-IgG Fab92
fragments conjugated to HRP (Jackson ImmunoResearch;
109–036-088) were diluted 1:5,000 in PBS-T, added to the plates,
and incubated again for 1 h at room temperature. Between each
step, the plates were washed with PBS-T four times. Plates were
finally developed using TMB substrate (Thermo Fisher Scien-
tific; 34021); the reactionwas stopped using 1M sulfuric acid and
the plates read at 450 nm. Sera were screened for binding at 1:
500 dilution. Recombinant monoclonal antibodies were diluted
to 10 µg/ml and serially diluted 1:3; the half effective concen-
tration (EC50) was determined by nonlinear regression analysis
using Prism 8 (GraphPad). For cross-binding assays, recombi-
nant antibodies were assayed at 1 µg/ml according to the pro-
tocol described above using the panel of flavivirus EDIII
proteins. The anti-HIV monoclonal antibody 10–1074 was used
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as isotype control (Mouquet et al., 2012). Antibodies with optical
density >2.5 times isotype control signal were considered cross-
reactive. The TBEV clinical tests (Table S1) were conducted using
the EIA TBE Virus IgG (TBG096) and EIA TBE Virus IgM
(TBM096) kits from TestLine Clinical Diagnostics.
Viruses and cells
The low-passage TBEV strain Hypr was provided by the Collection
of Arboviruses, Institute of Parasitology, Biology Centre of the
Czech Academy of Sciences, Ceske Budejovice, Czech Republic
(http://www.arboviruscollection.cz/index.php?lang=en). The
virus was originally isolated from the blood of a diseased
10-yr-old child in Brno, Czech Republic (formerly Czechoslo-
vakia), in 1953. Prior to the use in in vitro and in vivo ex-
periments, the virus was propagated in suckling mouse brains
and/or BHK-21 cells.
PS (porcine kidney stable) cells (Kozuch and Mayer, 1975)
were cultured at 37°C in Leibovitz (L-15) medium supplemented
with 3% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, and
1% L-glutamine (Sigma-Aldrich).
Plaque assay
To determine virus titer, plaque assays were performed as
previously described (De Madrid and Porterfield, 1969), with
slight modifications (Pokorna Formanova et al., 2019). Briefly,
10-fold dilutions of virus plus a suspension of PS cells (1.3 × 105
cells per well) were added to 24-well tissue culture plates. After
4 h of incubation at 37°C with 0.5% CO2, each well was overlaid
with carboxymethylcellulose (1.5% in L-15 medium). After a 5-d
incubation at 37°C and 0.5% CO2, the cell monolayers were vi-
sualized using naphthalene black. Viral titers were expressed as
PFU per milliliter.
Virus neutralization test
The virus neutralization test was performed as described pre-
viously (Širmarová et al., 2014), with several modifications.
Briefly, monoclonal antibodies (T025, T028, T034, and T038)
were diluted to 2.5 µg/ml in L-15 medium and then serially di-
luted 1:2 in 96-well plates. Diluted monoclonals were incubated
with 50 PFU per well of TBEV-Hypr (sufficient to cause 90–95%
cytolysis) for 90 min at 37°C. Thereafter, 5 × 104 PS cells were
added per well. After 4-d incubation (37°C), the cytopathic effect
was monitored microscopically, and cell viability was measured
using the Cell Counting Kit-8 (Dojindo Molecular Technologies)
according to the manufacturer’s instructions. IC50 was calcu-
lated from two independent experiments done in octuplicates
using GraphPad Prism (GraphPad Software; version 7.04).
Virus neutralization was also assayed using a fluorescence-
based virus neutralization test. Monoclonal antibodies (T025,
T028, T034, and T038; 10–1074 was used as an isotype control)
were incubated with TBEV, and PS cells were infected as de-
scribed above. The cells were incubated for 48 h at 37°C. The
cell monolayers were fixed with cold acetone/methanol (1:1),
blocked with 10% FBS, and incubated with mouse anti-flavivirus
antibody (Sigma-Aldrich; 1:250 dilution, clone D1-4G2-4-15;
catalog no. MAB10216). After washing, the cells were labeled
with secondary goat anti-mouse antibody conjugated to FITC
(Sigma-Aldrich; diluted 1:500, catalog no. AP181F) and coun-
terstained with DAPI (diluted to 1 µg/ml) to visualize cell nuclei.
The fluorescence signal was recorded with an Olympus IX71
epifluorescence microscope and processed by ImageJ software.
Statistical analyses
Data were analyzed using Mann–Whitney tests or ANOVA and
Tukey’s multiple comparison tests as specified and comparison
of survival curves was analyzed by log-rank (Mantel–Cox) test,
calculated in GraphPad Prism (version 8.4.3). P values < 0.05
were considered significant.
Crystallization, structure determination, and refinement
Complexes for crystallization were produced by mixing Fab and
antigen at a 1:1 molar ratio and incubating at room temperature
for 1–2 h. Crystals of T025 Fab–TBEVWE EDIII-His-Avitag com-
plex (space group P21; a = 55.5 Å, b = 66.7 Å, c = 91.2 Å, α = 90°,
β = 94.6°, γ = 90°; one complex per asymmetric unit) were ob-
tained by combining 0.2 µl crystallization complex with 0.2 µl of
0.1M sodium citrate tribasic dihydrate, pH 5.0, 10% PEG 6000 in
sitting drops at 22°C. Crystals of T025 Fab–TBEVFE EDIII-His-
Avitag complex (space group P21212; a = 56.96 Å, b = 69.72 Å, c =
180.20 Å, α = 90°, β = 90°, γ = 90°; one complex per asymmetric
unit) were obtained by combining 0.2 µl crystallization complex
with 0.2 µl of 0.1 M sodium citrate tribasic dihydrate, pH 5.0,
10% PEG 6000 in sitting drops at 22°C. Crystals of T025 Fab–
TBEVSi EDIII complex (space group P21; a = 55.4 Å, b = 67.2 Å, c =
91.2 Å, α = 90°, β = 94.8°, γ = 90°; one complex per asymmetric
unit) were obtained by combining 0.2 µl crystallization complex
with 0.2 µl of 5% (±)-2-methyl-2,4-pentanediol, 0.1 M Hepes, pH
7.5, 10% PEG 10,000 in sitting drops at 22°C. Crystals were
cryoprotected with 25% glycerol before being cryopreserved in
liquid nitrogen.
X-ray diffraction data were collected at Stanford Synchrotron
Radiation Lightsource Beamline 12–2 using a Dectris Pilatus 6M
detector. The data were integrated using Mosflm (Battye et al.,
2011) and scaled using CCP4 (Winn et al., 2011). The T025-
TBEVWE EDIII complex structure was solved by molecular re-
placement using the VHVL domains from PDB accession no.
2GHW, the CHCL domains from PDB accession no. 4OGX, and
TBEV EDIII from PDB accession no. 6J5F as search models in
PHASER (McCoy et al., 2007). The model was refined to 2.24 Å
resolution using an iterative approach involving refinement in
Phenix (Adams et al., 2010) and manual rebuilding into a sim-
ulated annealed composite omit map using Coot (Emsley and
Cowtan, 2004). Residues that were disordered and not in-
cluded in the model were HC residues 131–132, 214–219 and the
6XHis tag; residue 214 of the LC; and residues 299–302, 397, and
the 6XHis tag and Avi tag of the TBEVWE EDIII domain. The
T025-TBEVFE EDIII and T025-TBEVSi EDIII complex structures
were solved similarly using the partially refined T025-TBEVWE
EDIII structure as the molecular replacement model. The T025-
TBEVFE EDIII model was refined to 2.35 Å resolution, and the
T025-TBEVSi EDIII model was refined to 1.86 Å resolution using
the iterative approach described for T025-TBEVWE EDIII. The
Kabat numbering scheme was used for Fab numbering. Struc-
tures were superimposed, RMSDs were calculated, and figures
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were generated using PyMOL. Buried surface areas and hydro-
gen bonds were determined using PDBePISA (Krissinel and
Henrick, 2007). Fab-antigen contact residues were identified
as residues in which any atom is within 4 Å of an atom on the
other protein. The distance and geometry criteria used for as-
signing hydrogen bonds were a distance of <4.0 Å and a hy-
drogen bond angle of 90–270°. The maximum distance allowed
for a van der Waals interaction was 4.0 Å.
Animal ethics statement
The research complied with all relevant European Union
guidelines for work with animals and was in accordance with
Czech national law guidelines on the use of experimental ani-
mals and protection of animals against cruelty (Animal Welfare
Act No. 246/1992 Coll.). The protocol was approved by the
Committee on the Ethics of Animal Experimentation of the In-
stitute of Parasitology and the Departmental Expert Committee
for the Approval of Projects of Experiments on Animals of the
Czech Academy of Sciences (permit no. 4253/2019).
Mice and virus inoculation
Specific pathogen–free BALB/c mice were obtained from EN-
VIGO RMS. Sterilized pellet diet and water were supplied ad
libitum. In all experiments, female mice aged 6–8 wk were used.
Mice were housed in individually ventilated plastic cages
(Techniplast) with wood-chip bedding, with a constant tem-
perature of 22°C, a relative humidity of 65%, and under a 12-h
light/dark cycle. Three mice per group were used in experi-
ments. Mice were inoculated i.p. 1 d before or 1, 3, or 5 d after
infection with monoclonal antibodies T025 or 10–1074 in 200 μl
PBS and infected subcutaneously with 100 PFU TBEV-Hypr
(propagated eight times in suckling mouse brains). Mice were
monitored for symptoms and survival over time and euthanized
when reaching a humane endpoint.
Online supplemental material
Fig. S1 shows correlations between clinical or demographic data,
donor serum RVP neutralization or EDIII binding profiles, and
RVP neutralization curves for vaccinee serum. Fig. S2 includes
the single-cell sorting strategy, somatic hypermutations, and
CDR3 length analysis for individual donors and all donors
grouped together, as well as hydrophobicity GRAVY scores. Fig.
S3 shows VH, VK, and VL gene frequencies; CDR3 sequence lo-
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Figure S1. Clinical correlations and serum neutralization in vaccinees. (A–F) Serum TBEV EDIII ELISA data (IgG) from Fig. 1 B plotted against demographic
and available clinical information. (G–L) Serum TBEV RVP neutralization data from Fig. 1 C plotted against demographic and available clinical information. A and
G show age (no significance), B and H show length of hospitalization (no significance), C and I show severity of disease (no significant differences), D and J show
IgM titers (IP) measured at the time of hospitalization (P = 0.0029 and P < 0.0001, respectively); E and K show IgG titers (Vienna units/ml) measured at the time
of hospitalization (P < 0.0001 and no significance, respectively), and F and L show patient gender (no significant differences). Statistical significance was
calculated for A, B, D, E, G, H, J, and K using two-tailed Spearman’s tests; for L and F using Mann–Whitney tests; and for C and I using one-way ANOVA with
Tukey’s test. (M) Correlation between serum TBEV EDIII ELISA (IgG) and RVP neutralization data. (N) TBEV RVP neutralization curves with sera from vac-
cinated PBMC donors. Representative of two experiments, each performed in triplicate. Data are presented as mean with standard deviation. (O) Summary of
serum NT50s for all infected and vaccinated PBMC donors. Related to Fig. 1 and Table S1. RLU, relative light units.
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Figure S2. Sorting strategy and antibody sequence analysis. (A) Sorting strategy. Forward and side scatter (FSC and SSC, respectively) were used to gate
on single lymphocytes. Dump channel included CD3, CD8, CD14, CD16, and a viability dye. CD20+ B cells that failed to bind OVA (OVA−) but did bind to the
TBEV EDIII bait coupled with both PE and AF647 fluorophores were purified. (B) For each donor, the number of V gene somatic nucleotide mutations is shown
on the left and the amino acid length of the CDR3 is shown on the right. (C) As in B, but for all donors combined. For B and C, horizontal red lines indicate the
mean. (D) Distribution of hydrophobicity GRAVY scores at the IGH CDR3 of antibodies from all donors combined and compared with human repertoire (Briney
et al., 2019). P < 0.0001 was determined using the Wilcoxon nonparametric test. Related to Fig. 2, Table S2, and Table S3.
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Figure S3. Antibody V gene frequency and CDR3 sequences. (A) Bar graph showing the frequency of V heavy gene usage in TBEV antibodies from infected
donors compared with human repertoire (Rubelt et al., 2012). (B and C) As in A, but for V kappa and V lambda genes. In A–C, orange indicates anti-TBEV
antibodies isolated in this study, while blue indicates control repertoire; P values were calculated using a two-tailed t test with unequal variances. (D) Sequence
logos for antibody CDR3s from infected donors generated by WebLogo. The height of the stack indicates the sequence conservation at a given position, while
the height of letters within the stack indicates the relative frequency of each amino acid at that position. (E) Examples of highly similar antibody sequences
found in multiple donors. Related to Fig. 2, Table S2, and Table S3.
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Figure S4. Antibody binding and neutralization. (A) ELISA binding curves to TBEVFE and TBEVSi EDIII for the 59 antibodies. Data are representative of two
experiments. (B) Top panel shows screening for infected donor antibodies binding to a panel of tick-borne flavivirus EDIIIs, including POWV-LB, POWV-DTV,
KFDV, LGTV, LIV, and OHFV. Antibodies were screened in duplicate at 1 µg/ml. Bottom panel shows screening for neutralization against RVPs corresponding to
the same panel of tick-borne flaviviruses. Infected donor antibodies were screened in triplicate at 1 µg/ml. (C) Screening for vaccine antibodies binding and
neutralization against a panel of tick-borne flavivirus EDIIIs and RVPs as in B. In B and C, gray indicates binding or neutralization over control. (D–I) Neu-
tralization curves of selected antibodies against tick-borne flavivirus RVPs other than TBEV. Representative of two experiments in triplicate. Error bars indicate
standard deviation. Related to Fig. 3, Table S4, and Table S5.
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Tables S1–S6 are provided online as separate Excel and Word files. Table S1 lists clinical data from TBEV-infected and vaccinated
donors. Table S2 lists sequences of anti-TBEV-EDIII IgG antibodies. Table S3 lists highly similar antibody sequences shared across
individuals. Table S4 lists sequences of cloned recombinant monoclonal antibodies. Table S5 lists effective and inhibitory
concentrations of recombinantly expressed monoclonal antibodies. Table S6 lists data collection and refinement statistics for the
crystal structures.
Figure S5. T025 antibody recognizes three subtypes of TBEV EDIII. (A) Overlay of crystal structures of T025 Fab bound to EDIII from three subtypes of
TBEV. Structures were aligned on all Cα atoms in the Fab–EDIII complex and shown as orange (T025-TBEVWE EDIII), blue (T025-TBEVFE EDIII), or green (T025-
TBEVSi EDIII) ribbons. RMSDs for Fab-EDIII alignments are 0.54 Å (T025-TBEVWE EDIII and T025-TBEVFE EDIII; 518 Cα atoms) and 0.26 Å (T025-TBEVWE EDIII
and T025-TBEVSi EDIII; 525 Cα atoms). The CHCL domains of the Fabs were omitted for clarity. (B) Sequence alignment of EDIIIs from three strains of TBEV.
Residues that contain an EDIII atom within 4 Å of an atom within a residue in T025 in each crystal structure are highlighted in orange. β-Strands are shown as
arrows and defined according to Rey et al. (1995). (C) Contact residues between T025 Fab and TBEVWE EDIII. Contacts were identified using AntibodyDatabase
(West et al., 2013) and defined as residues in which any atom is within 4 Å of an atom from a residue on the interacting partner. Related to Fig. 4.
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